Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ: AKRO )

50.52 +1.29 (+2.62%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 875,299
Open 49.24
Bid (Size) 47.24 (2)
Ask (Size) 51.97 (1)
Prev. Close 49.23
Today's Range 49.24 - 51.40
52wk Range 17.86 - 58.40
Shares Outstanding 50,086,978
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Stock Just Doubled in 1 Day -- Is It Still a Buy?
Via The Motley Fool
Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?
Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners... 
Via Benzinga

Performance

YTD
+79.91%
+79.91%
1 Month
+110.41%
+110.41%
3 Month
+70.91%
+70.91%
6 Month
+94.61%
+94.61%
1 Year
+141.84%
+141.84%

More News

Read More
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
From Akero Therapeutics Inc.
Via GlobeNewswire
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Royal Caribbean Cruises Posts Upbeat Earnings, Joins Brighthouse Financial, Invesco, Boeing And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
McDonald's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Akero Therapeutics Announces Proposed Public Offering of Common Stock
From Akero Therapeutics Inc.
Via GlobeNewswire
Which stocks are experiencing notable movement on Monday?
Via Chartmill
S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
These stocks are moving in today's session
Via Chartmill
Dow Edges Higher; AT&T Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks Fall Sharply Alongside Tech; VIX Soars
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Traders are paying attention to the gapping stocks in Monday's session.
Via Chartmill
Dada Nexus, Titan Machinery, AT&T And Other Big Stocks Moving Higher On Monday
Via Benzinga
Akero Stock Hits Over 18-Month High On MASH Trial Data: Citi Lauds ‘Best-Case Scenario,’ Retail Exuberant
Via Stocktwits
Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December
Via Benzinga
Topics Economy
Exposures Interest Rates
These stocks that are showing activity before the opening bell on Monday.
Via Chartmill
Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study
Via Investor's Business Daily
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.